30 years of historical data (1996–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioCryst Pharmaceuticals, Inc. trades at 7.2x earnings, 12% above its 5-year average of 6.4x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 69%. On a free-cash-flow basis, the stock trades at 5.4x P/FCF, 9% above the 5-year average of 4.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.7B | $1.6B | $1.2B | $2.1B | $2.5B | $1.2B | $399M | $833M | $415M | $467M |
| Enterprise Value | $1.8B | $1.6B | $2.3B | $1.9B | $2.6B | $2.6B | $1.3B | $369M | $868M | $419M | $498M |
| P/E Ratio → | 7.23 | 6.45 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.13 | 1.95 | 3.45 | 3.47 | 7.88 | 15.78 | 69.96 | 8.17 | 40.32 | 16.46 | 17.70 |
| P/B Ratio | — | — | — | — | — | — | — | 10.43 | — | — | — |
| P/FCF | 5.37 | 4.91 | — | — | — | — | — | — | — | — | — |
| P/OCF | 5.37 | 4.91 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
BioCryst Pharmaceuticals, Inc.'s enterprise value stands at 5.2x EBITDA, 10% above its 5-year average of 4.8x. The Healthcare sector median is 13.8x, placing the stock at a 62% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.86 | 5.08 | 5.63 | 9.49 | 16.35 | 70.37 | 7.56 | 42.02 | 16.64 | 18.90 |
| EV / EBITDA | 5.24 | 4.77 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 5.24 | — | 198.14 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 4.68 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
BioCryst Pharmaceuticals, Inc. earns an operating margin of 39.0%. Operating margins have expanded from -31.3% to 39.0% over the past 3 years, signaling improving operational efficiency. ROIC of 807.9% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8% | 97.8% | 97.2% | 98.6% | 97.6% | 95.4% | 90.6% | 91.6% | 97.7% | 93.2% | 89.8% |
| Operating Margin | 39.0% | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | -227.9% | -184.4% |
| Net Profit Margin | 30.2% | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.3% | -261.2% | -209.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -1925.4% | -284.7% | — | — | — |
| ROA | 52.5% | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | -49.1% | -51.4% |
| ROIC | 807.9% | 807.9% | -0.7% | -38.8% | -179.6% | — | — | — | — | — | — |
| ROCE | 105.2% | 105.2% | -0.7% | -25.6% | -32.0% | -49.8% | -112.0% | -124.1% | -104.2% | -82.7% | -101.7% |
Solvency and debt-coverage ratios — lower is generally safer
BioCryst Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 0.0x, which is very conservative (99% below the sector average of 3.1x). The company holds a net cash position — cash of $90M exceeds total debt of $12M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 2.21 | — | — | — |
| Debt / EBITDA | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | — | -0.77 | — | — | — |
| Net Debt / EBITDA | -0.23 | -0.23 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.22 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -0.03 | -0.96 | -1.50 | -3.00 | -12.05 | -8.36 | -10.27 | -6.70 | -7.49 |
Net cash position: cash ($90M) exceeds total debt ($12M)
Short-term solvency ratios and asset-utilisation metrics
BioCryst Pharmaceuticals, Inc.'s current ratio of 2.06x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.31x to 2.06x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.06 | 2.06 | 2.63 | 3.31 | 4.90 | 5.46 | 3.06 | 1.78 | 1.65 | 1.68 | 1.23 |
| Quick Ratio | 2.03 | 2.03 | 2.58 | 3.12 | 4.63 | 5.31 | 3.00 | 1.78 | 1.62 | 2.18 | 1.22 |
| Cash Ratio | 1.40 | 1.40 | 2.00 | 2.59 | 4.02 | 4.89 | 2.84 | 1.48 | 1.50 | 1.53 | 1.01 |
| Asset Turnover | — | 1.70 | 0.92 | 0.64 | 0.49 | 0.27 | 0.05 | 0.28 | 0.14 | 0.14 | 0.29 |
| Inventory Turnover | 3.53 | 3.53 | 1.54 | 0.16 | 0.24 | 0.46 | 0.24 | — | 0.29 | — | 5.40 |
| Days Sales Outstanding | — | — | 64.03 | 62.72 | 68.19 | 68.31 | 177.17 | 165.52 | 75.87 | 88.65 | 121.44 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioCryst Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 13.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 13.8% | 15.5% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 18.6% | 20.4% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $219M | $207M | $192M | $186M | $179M | $167M | $116M | $103M | $84M | $74M |
Compare BCRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BCRXYou | $2B | 7.2 | 5.2 | 5.4 | 97.8% | 39.0% | — | 807.9% | 0.0 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BCRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonBioCryst Pharmaceuticals, Inc.'s current P/E ratio is 7.2x. The historical average is 6.4x. This places it at the 100th percentile of its historical range.
BioCryst Pharmaceuticals, Inc.'s current EV/EBITDA is 5.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 4.8x.
Based on historical data, BioCryst Pharmaceuticals, Inc. is trading at a P/E of 7.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BioCryst Pharmaceuticals, Inc. has 97.8% gross margin and 39.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
BioCryst Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.